Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The OvIP1 study is designed to examine how drug dose and perfusion temperature affect the
pharmacokinetics and pharmacodynamics of cisplatin used as (hyperthermic) intraperitoneal
chemoperfusion, as an adjunct to surgery, in women with stage III epithelial ovarian cancer.